文献速递肝胆胰外科围术期管理与 ERAS

早期胰腺癌胰腺切除术的价值定义

Defining Value for Pancreatic Surgery in Early-Stage Pancreatic Cancer.
PubMed 文献 · JAMA Surg · 2019-10-16

该回顾性队列研究纳入2786例I-II期胰腺癌切除患者,分析患者与医院特征同总生存、费用及价值的关系。术后化疗与高容量中心同更优生存相关,并发症、再入院和住院时间延长同更高费用相关;NCI指定中心与高容量中心并未带来更高价值。

要点

  • 术后化疗与高容量中心同更优总生存相关。
  • 并发症、再入院和住院时间延长同更高费用相关。
  • NCI指定中心与高容量中心未显示更高价值。

核心结论

  • 高价值医疗同重要患者特征和术后结局相关,但NCI指定中心与高容量中心未带来更高价值。
  • 数据提示这些中心可能需要针对性措施以提升价值。

研究设计与样本

  • 回顾性队列研究,纳入2004年1月1日至2012年12月31日在157家医院接受胰腺切除术的2786例I-II期胰腺癌患者。
  • 数据来自加州癌症登记处与州卫生规划发展办公室数据库链接,分析时间为2017年11月11日至2018年9月4日。

主要发现

  • 术后化疗(aHR 0.71;95%CI 0.64-0.79;P<.001)与高容量中心(aHR 0.78;95%CI 0.61-0.99;P=.04)同更优总生存相关。
  • Elixhauser合并症指数评分(估计值0.006;95%CI 0.003-0.008)、并发症(估计值0.22;95%CI 0.17-0.27)、再入院(估计值0.34;95%CI 0.29-0.39)和更长住院时间(估计值0.03;95%CI 0.03-0.04)同更高费用相关(P<.001)。
  • 术后化疗同更低费用相关(估计值-0.06;95%CI -0.11至-0.02;P=.006)。
  • NCI指定中心与高容量中心同费用无关。

关键数值与推荐

  • 高价值定义为生存第四五分位或更高且费用第二五分位或更低。
  • III和IV级肿瘤(OR 0.65;95%CI 0.39-0.91;P=.001)、T3分期(OR 0.71;95%CI 0.46-0.95;P=.005)、并发症(OR 0.68;95%CI 0.49-0.86;P<.001)、再入院(OR 0.64;95%CI 0.44-0.84;P<.001)和住院时间(OR 0.82;95%CI 0.78-0.85;P<.001)同高价值医疗呈负相关。
  • NCI指定(OR 1.07;95%CI 0.66-1.49;P=.74)与高容量中心(OR 1.08;95%CI 0.54-1.61;P=.07)同高价值医疗无关。

临床怎么用

  • 在早期胰腺癌胰腺切除术中,应重视术后化疗、减少并发症与再入院、缩短住院时间以提升价值。
  • 不能仅凭NCI指定或高容量中心身份推断其提供更高价值医疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Value-based care is increasingly important, with rising health care costs and advances in cancer treatment leading to greater survival for patients with cancer. Regionalization of surgical care for pancreatic cancer has been extensively studied as a strategy to improve perioperative outcomes, but investigation of long-term outcomes relative to health care costs (ie, value) is lacking. OBJECTIVE: To identify patient and hospital characteristics associated with improved overall survival, decreased costs, and greater value among patients with pancreatic cancer undergoing curative resection. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study identified 2786 patients with stages I to II pancreatic cancer who underwent pancreatic resection at 157 hospitals from January 1, 2004, through December 31, 2012. The study used the California Cancer Registry, which collects data from all California residents newly diagnosed with cancer, linked to the Office of Statewide Health Planning and Development database, which collects administrative data from all California licensed hospitals. Data were analyzed from November 11, 2017, through September 4, 2018. EXPOSURES: Pancreatic resection at high-volume and/or National Cancer Institute (NCI)-designated cancer centers. MAIN OUTCOMES AND MEASURES: The primary outcomes were overall survival, surgical hospitalization costs, and value. High value was defined as the fourth quintile or higher for survival and the second quintile or less for costs. Costs were calculated from charges using cost-charge ratios and adjusted for geographic variation and inflation. Multivariable regression models were used to determine factors associated with overall survival, costs, and high value. RESULTS: Among the 2786 patients included (1394 [50.0%] male; mean [SD] age, 67.0 [10.7] years), postoperative chemotherapy (adjusted hazard ratio [aHR], 0.71; 95% CI, 0.64-0.79; P < .001) and high-volume centers (aHR, 0.78; 95% CI, 0.61-0.99; P = .04) were associated with greater overall survival. Higher Elixhauser comorbidity index scores (estimate, 0.006; 95% CI, 0.003-0.008), complications (estimate, 0.22; 95% CI, 0.17-0.27), readmissions (estimate, 0.34; 95% CI, 0.29-0.39), and longer lengths of stay (estimate, 0.03; 95% CI, 0.03-0.04) were associated with higher costs (P < .001), whereas postoperative chemotherapy was associated with lower costs (estimate, -0.06; 95% CI, -0.11 to -0.02; P = .006). National Cancer Institute-designated and high-volume centers were not associated with costs. Although grades III and IV tumors (odds ratio [OR], 0.65; 95% CI, 0.39-0.91; P = .001), T3 category disease (OR, 0.71; 95% CI, 0.46-0.95; P = .005), complications (OR, 0.68; 95% CI, 0.49-0.86; P < .001), readmissions (OR, 0.64; 95% CI, 0.44-0.84; P < .001), and length of stay (OR, 0.82; 95% CI, 0.78-0.85; P < .001) were inversely associated with high-value care, NCI designation (OR, 1.07; 95% CI, 0.66-1.49; P = .74) and high-volume centers (OR, 1.08; 95% CI, 0.54-1.61; P = .07) were not. CONCLUSIONS AND RELEVANCE: In this study, high-value care was associated with important patient characteristics and postoperative outcomes. However, NCI-designated and high-volume centers were not associated with greater value. These data suggest that targeted measures to enhance value may be needed in these centers.

来源:JAMA Surg,查看原文。版权归原作者所有。

引用

  1. Bateni SB, Gingrich AA, Hoch JS, et al. Defining Value for Pancreatic Surgery in Early-Stage Pancreatic Cancer. JAMA Surg. 2019. PMID: 31433465. doi:10.1001/jamasurg.2019.3019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。